Abstract
Microneedles (MNs) are a novel transdermal drug delivery platform, rapidly progressing from a substantive evidence base, towards commercialisation. As part of this transition, it is important to consider the future use of MNs by older people in order to ensure optimal therapeutic outcomes for this unique and increasing population group. This paper, therefore, considers the use of MNs by those aged over 65 years, investigating insertion parameters in ageing skin, alongside the feasibility and acceptability of the technology. Hydrogel-forming MN arrays were applied to seven subjects aged over 65 years, with breach of the stratum corneum confirmed using optical coherence tomography. Insertion depths recorded in each case were similar to a comparative group, aged 20–30 years. Skin recovery was, however, demonstrated to occur at a slower rate in the older subjects, as measured using transepidermal water loss. Qualitative methods, including focus groups and semi-structured interviews, were employed to collect the views and opinions of older people and community pharmacists respectively. The overall consensus was positive, with a number of benefits to MN-mediated drug delivery identified, such as reduced dosing frequency, improved adherence and an alternative delivery route where oral or injectable medication was precluded. Concerns centred on practical issues associated with age-related functional decline, including, for example, reduced dexterity and skin changes. The presentation of this work collectively provides the first convincing report of the importance of further translational research in this area to support future MN use in older people, ensuring an age-appropriate delivery platform.
Highlights
It is evident that the global population is ageing, with the number of people aged over 65 years increasing faster than any other age group [1]
The mean insertion depths and pore widths upon MN application were measured as shown in Fig. 2, and the Transepidermal water loss
The initial baseline transepidermal water loss (TEWL) differed significantly between the two age groups (p < 0.0001), with a mean value of 4.94 g/m2 h measured in the ≥65 year olds, compared to 9.31 g/m2 h in the 20–30 year olds
Summary
It is evident that the global population is ageing, with the number of people aged over 65 years increasing faster than any other age group [1]. Transdermal drug delivery has a number of pertinent advantages for the older adult, offering a viable alternative to oral delivery, with the potential to provide sustained release and minimise adverse effects [5]. Aligning these opportunities alongside the typically high medication consumption of the
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
